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3) To	 identify	 the	 role	 of	 Fsp27β	 in	 PPARα	 signaling	 by	 studying	 its	 ability	 to	






















Deregulation	 of	 lipid	 metabolism	 lies	 at	 the	 base	 of	 the	 most	 common	 medical	
disorders	 in	 western	 populations,	 such	 as	 cardiovascular	 disease,	 obesity,	 diabetes,	
and	 fatty	 liver	 conditions.	However,	 a	 gap	of	 knowledge	 still	 exists	 in	both	 the	basic	
science	and	the	clinical	 fields	regarding	the	 impact	of	altered	 lipid	storage	on	human	
disease.	
The	liver	can	both	oxidize	and	synthetize	fatty	acids.	In	humans	the	overall	rate	of	fatty	
acid	 synthesis	 from	 other	 molecules	 (glucose	 in	 particular)	 is	 usually	 small	 in	









fasting.	 The	plasma	hormone	profile	 in	 this	 situation,	 low	 insulin	 and	high	 glucagon,	
induces	the	release	of	large	amounts	of	fatty	acids	from	the	adipose	tissue	to	be	used	
by	peripheral	tissues	and	spare	glucose	consumption.	Therefore,	the	liver	of	a	starved	
animal	 actively	 oxidizes	 fatty	 acid,	 which	 provides	 the	 energy	 necessary	 to	 sustain	
gluconeogenesis.	 It	 also	 supplies	 the	 acetyl-CoA	 needed	 for	 active	 ketone	 body	
synthesis,	 which	 replaces	 glucose	 as	 the	 energy	 substrate	 for	 the	 brain	 and	 other	
tissues	(McGarry	and	Foster	1995).		
Two	 enzymes	 determine	 the	 metabolic	 fate	 of	 fatty	 acids	 in	 the	 liver	 of	 starved	
animals:	 carnitine	 palmitoyltransferase-1	 (CPT1)	 A	 and	 hydroxymethylglutaryl	 CoA	
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synthase	2	 (HMGCS2).	Cpt1A	 encodes	a	malonyl-CoA-sensitive	protein	 that	 regulates	
mitochondrial	 long	 chain	 fatty	 acid	 oxidation	 (McGarry	 and	 Foster	 1995),	 whereas	
Hmgcs2	encodes	a	mitochondrial	protein	that	controls	the	3-hydroxy-3-methylglutaryl-
CoA	 (HMG-CoA)	 cycle,	 by	 which	 acetoacetate,	 b-hydroxybutyrate,	 and	 NAD+	 are	
generated	 (Hegardt	1995).	 The	expression	of	both	genes	 is	 regulated	by	peroxisome	
proliferator-activated	receptor	α	(PPARα)	(Napal,	Marrero,	and	Haro	2005;	Ortiz	et	al.	
1999;	Rodríguez	et	al.	1994;	Hsu	et	al.	2001),	 a	 fatty	acid-activated	nuclear	 receptor	
that	 regulates	metabolic	 changes	 in	 the	 liver	 associated	with	 starvation	 (see	below).	
Consistently,	 during	 starvation,	 PPARα	 null	 mice	 show	 severe	 hypoglycemia	 and	







Figure	 I1.	 Role	 of	 liver	 FAO	 in	 generating	 the	 energy	 and	 reduction	 power	 needed	 to	 produce	 glucose	 during	
fasting.	 Energy	 is	 obtained	 from	 FAO	 to	 perform	 gluconeogenesis	 from	 precursors	 (lactate,	 glycerol	 or	 alanine).	
Complete	oxidation	of	FA	is	compromised	by	the	gluconeogenic	use	of	oxaloacetate.	Ketone	body	production	allows	
the	 incomplete	b-oxidation	 and	 liberates	 the	 Ac-CoA	molecule	 needed	 for	 fatty	 acid	 activation.	 Gluconeogenesis	




In	addition	 to	 this	network	of	genes	 regulated	by	PPARα	activation,	another	enzyme	
may	 contribute	 to	 the	metabolic	 adaptation	 to	 fasting:	 SirT1	 (sirtuin	 1).	 This	 NAD+-
dependent	 protein	 deacetylase	 is	 a	 general	 regulator	 of	 energy	 homeostasis	 in	
response	 to	 nutrient	 availability	 (Nemoto,	 Fergusson,	 and	 Finkel	 2004).	 Thus,	 the	
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adaptation	 program	 to	 fasting	 in	 liver	 can	 be	 divide	 into	 two	 temporally	 distinct	
phases:	 the	 onset	 of	 fasting	 (<12–18	 h)	 and	 sustained	 fasting	 (>12–18	 h)	 that	 are	
distinguishable	 by	 the	 NAD+	 mediated	 SirT1	 activation	 (Dominy	 et	 al.	 2010).	 The	









of	 glucagon	 and	 a	 decrease	 in	 insulin.	 In	 the	 first	 phase	 of	 fasting	 (<12h-18h)	
gluconeogenesis	is	upregulated	in	liver.	The	transcription	of	gluconeogenic	enzymes	is	
initiated	 by	 activation	 of	 cAMP	 response	 element	 binding	 protein	 (CREB)	 and	 its	
coactivator	 CRTC2.	 However,	 in	 longer	 periods	 of	 fasting	 (>12-18h)	 CRTC2	 protein	
degradation	 is	 signaled	 by	 SIRT1	 deacetylation	 (Lay	 et	 al.	 2010).	 Therefore,	 the	
maintenance	of	the	gluconeogenic	response	in	prolonged	fasting	will	be	mediated	by	
PGC1-α and	 its	 related	 transcription	 factors	 (Figure	 I2).	 An	 increase	 in	 PGC1α	 levels	




several	 transcription	 factor.	 Thus,	 SIRT1	 may	 support	 residual	 expression	 of	 the	
gluconeogenic	program	during	late	fasting	by	deacetylation	and	enhancing	the	activity	











Figure	 I2.	 A	 proposed	 theory	 for	 the	 temporal	 regulation	 of	 two	 major	 transcriptional	 coactivators	 involved	 in	








CREBH	 (CREBH:	 cyclic-AMP-responsive	element	binding	protein	H)	 is	 an	 Endoplasmic	
Reticulum	 transcription	 factor,	 which	 possesses	 similarity	 to	 SREBP	 as	 regards	 its	
localization	and	the	activation	process	of	its	cleavage	system.	CREBH	is	involved	in	the	








element).	 CREBH	 also	 stimulates	 FAO	 and	 ketogenesis	 in	 the	 liver	 of	 fasted	 animals	
throughout	an	indirect	mechanism	that	involves	FGF21,	a	unique	member	of	the	FGF	
family	 with	 hormone-like	 actions(Kharitonenkov,	 A.	 Shiyanova	 et	 al.	 2005).	 CREBH	
directly	 binds	 to	 the	 proximal	 region	 of	 the	 Fgf21	 promoter	 and	 upregulates	 its	
expression	 (H.	 Kim	et	 al.	 2014).	 FGF21	 is	 a	 key	mediator	of	 starvation	 that	 activates	
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lipolysis	 in	 white	 adipose	 tissue	 (WAT)	 and	 increases	 fatty	 acid	 oxidation	 and	
ketogenesis	in	the	liver	(Kharitonenkov,	A.	Shiyanova	et	al.	2005).		
Fgf21	is	also	a	bona	fide	PPARα	target	gene	(Badman	et	al.	2007;	Inagaki	et	al.	2007),	
although	 the	 presence	 of	 CREBH	 is	 needed	 for	 the	 PPARa-mediated	 Fgf21	 induction	
during	 fasting	 (Danno	et	al.	2010).	 In	addition,	CREBH	 is	acetylated	 in	 the	 liver	upon	
fasting	 in	 a	 time-dependent	 manner	 and	 this	 acetylation	 is	 crucial	 to	 maintain	 the	
hepatic	 lipid	homeostasis	 in	a	 fasting	 state	 (Hyunbae	Kim	et	al.	 2015a).	 Therefore,	 a	
cooperative	 model	 (Figure	 I3)	 between	 CREBH	 and	 PPARα	 has	 been	 proposed	 to	
explain	 upregulation	 of	 Fgf21	 expression	 by	 both	 CREBH	 and	 PPARα	 (Danno	 et	 al.	
2010;	Hyunbae	Kim	et	al.	2015a).	In	this	model,	upon	states	of	fasting,	cleavage	of	the	
CREBH	 protein	 occurs	 (see	 below).	 The	 cleaved	 activated	 form	 of	 CREBH	 will	 be	
released	 and	 moved	 to	 the	 nucleus,	 where	 the	 histone	 acetyltransferase	 PCAF	
mediates	 the	 acetylation	 of	 CREBH	 at	 K294.	At	 the	 same	 time,	 SIRT1	modulates	 the	
acetylation	 phenomenon	 through	 its	 deacetylation	 activity	 (Figure	 I3).	 Globally,	 this	











NEFAs	 arriving	 from	 WAT	 are	 involved	 in	 the	 CREBH	 nuclear	 protein	 accumulation	
under	fasting	by	promoting	CREBH	cleavage.	Hence,	in	the	fasted	state,	the	expression	
of	CREBH	mRNA	and	nuclear	protein	are	both	suppressed	by	refeeding	in	the	wild-type	
mice,	 but	not	 in	 the	ob/ob	mice	 (Danno	et	 al.	 2010).	 Interestingly,	 animals	 in	which	
WAT	 lipolysis	 has	 been	 ablated	 (CGI-58-ATko),	 and	 there	 is	 not	 a	 FA	 supply	 upon	
fasting,	 shown	 a	 marked	 defect	 in	 liver	 PPARa-signaling	 and	 nuclear	 CREBH	
translocation	 (Jaeger	 et	 al.	 2015).	 Therefore,	 CREBH	 cleavage	 in	 the	 ER	 could	 be	
relevant	 to	 signaling	 the	 presence	 of	 this	 old	 fat	 (see	 below)	 in	 liver	 throughout	
PPARα-mediated	FGF21	activation	(Figure	I4)	
	
Figure	 I4.	 Proposed	 moldel	 for	 FA	 stimulation	 of	 CREBH	 translocation	 to	 nucleus.	 CGI-58,	 Comparative	 gene	
identification-58	 (ATGL	 co-activactor);	 G0S2,	 G0/G1	 Switch	 Gene	 2	 (ATGL	 inhibitor);	 ATGL,	 Adipose	 triglyceride	
lipase;	 AOX;	 Acyl-CoA	 oxidase;	 MCAD,	 Medium-chain	 acyl-CoA	 dehidrogenase;	 LCAD,	 Long-chain	 acyl-CoA	















a	 repetitive	 consensus	 hexamer	 (AGGTCA)	 that	 is	 recognized	 by	 the	 DNA	 binding	







the	 metabolic	 homeostasis	 by	 controlling	 the	 metabolism	 of	 glucose	 and	 lipids,	
(Monsalve	et	al.	2013).	For	the	PPAR-mediated	transcriptional	activation	of	 its	 target	
genes	 it	 is	necessary	 the	heterodimerization	of	a	PPAR	with	RXR,	and	 the	binding	of	
the	 heterodimer	 to	 a	 PPRE	 sequence,	 producing	 a	 change	 in	 chromatin	 structure	
indicated	by	 ligand	activation	of	 the	complex	and	histone	H1	release.	The	binding	of	
the	 ligand	 triggers	 a	 conformational	 change	 that	will	 generate	 new	 specific	 contacts	















The	 alpha	 isoform	 of	 the	 PPARs	 (PPARα)	 has	 a	 crucial	 role	 in	 FAO	 and	 therefore	 is	
found	mainly	in	highly	oxidative	tissues,	its	mRNA	is	expressed	in	liver,	and	at	a	lesser	
extent	in	heart,	kidneys,	skeletal	muscle	and	BAT.	PPARa	is	shown	to	have	a	crucial	role	
in	 the	 adaptive	 response	 to	 fasting	 by	 regulating	 genes	 involved	 in	 FAO	 (Napal,	
Marrero,	and	Haro	2005;	Rodríguez	et	al.	1994),	therefore	having	consequent	indirect	
effects	 on	 other	 metabolic	 pathways	 and	 energy	 homeostasis(Kersten	 et	 al.	 1999;	
Desvergne,	Michalik,	and	Wahli	2006;	Evans	2004).	
	
PPARψ	 is	 highly	 enriched	 in	 both	 BAT	 and	 WAT.	 It	 is	 induced	 during	 adipocyte	
differentiation	and	 it	 is	 thought	 to	be	an	 important	 regulator	of	 fat	 cells(Lazar	2002;	
Tsai,	 Y.S.,	 and	 Maeda	 2005).	 This	 member	 of	 the	 PPARs	 is	 a	 master	 effector	 of	
adipogenesis	 in	a	transcriptional	cascade	 involving	C/EBP	(Z.	Wu	et	al.	1999)	and	has	
an	important	role	in	the	regulation	of	glucose	and	lipid	metabolism.	It	also	participates	
















The	 transcriptional	 activation	 of	 PPARδ	 enhances	 fatty	 acid	 catabolism	 and	 energy	
uncoupling,	 decreasing	 TG	 stores,	 improving	 endurance	 performance	 and	 enhancing	
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In	muscle	 it	 is	 attributed	a	 fundamental	 role	 in	 the	 regulation	of	mitochondrial	 fatty	
acid	 oxidation.	 Thus,	 overexpression	 of	 PPARδ	 in	 muscle	 increases	 the	 oxidative	


















synthetizing	 fatty	 acid	 from	 carbohydrate,	 by	 the	 deletion	 of	 fatty	 acid	 synthase	
(FASN).	 This	 animal	 when	 either	 fed	 with	 a	 fat	 free	 diet	 or	 exposed	 to	 prolonged	
fasting	 showed	 the	 same	 hypoglycemic	 phenotype	 than	 PPARα-null	 mice,	 with	














Figure	 I5.	“Proposed	model	 for	differential	effects	of	hepatic	 lipid.	Fat	absorbed	from	the	diet	or	synthesized	de	
novo	 via	 FAS	 in	 the	 liver	 constitutes	 “new”	 fat,	 capable	 of	 activating	 PPARα	 to	 ensure	 normal	 glucose	 and	 lipid	
homeostasis.	 Fat	 derived	 from	 peripheral	 mobilization	 of	 adipose	 stores	 constitutes	 a	 different	 hepatic	
compartment	(“old”	fat)	that	does	not	appear	to	activate	PPARα	as	effectively	as	new	fat,	leading	to	fatty	liver.	In	














PPARδ	 overexpression	 (adenoviral-mediated	 PPARδ)	 up-regulates	 glucose	 utilization	
and	de	novo	 lipogenesis	pathways	 (S.	Liu	et	al.	2011).	Liver-specific	PPARδ	activation	
increases,	whereas	 hepatocyte-PPARδ	 deletion	 reduces,	muscle	 fatty	 acid	 uptake	 (S.	




that	 the	 main	 differences	 in	 serum	 occurred	 during	 the	 dark	 cycle,	 when	
PPARδ controlled	 lipogenesis	 is	 active.	 Nonetheless,	 daytime	 feeding	 led	 to	 serious	




by	 PPARd	 overexpression	 (adPPARδ).	 While	 transitory	 Acc1	 knockdown	 (LACC1KD)	
mice	 shows:	 i)	 reduced	 hepatic	 TAG,	 ii)	 increased	 serum	 TAG,	 and	 iii)	 decrease	 FFA	
uptake	in	isolated	soleus	muscle.	Muscle	FA	uptake	decreased	in	LACC1KD	mice	in	the	
dark/feeding	cycle,	when	the	lipogenic	program	is	active	and	additionally	there	was	a	
slower	 clearance	of	 circulating	 [3H]	oleic	 acid.	 Thus,	de	novo	 lipogenesis	 is	 linked	 to	
muscle	FA	use(S.	Liu	et	al.	2013).	
	
Unbiased	 metabolite	 profiling	 identifies	 1-stearoyl-2-oleoyl-sn-glycero-3-
phosphocholine	 (PC	 18:1/18:0)	 as	 a	 serum	 lipid	 regulated	 by	 diurnal	 hepatic	 PPARδ	




PPARδ expression	peaks	 at	 night,	 parallel	 to	 the	mRNA	 levels	 of	 the	molecular	 clock	
Bmal1	in	the	liver.	Therefore,	 it	 is	feasible	that	hepatic	PPARδ	alter	the	expression	of	
muscle	genes	and	FA	use	through	PC	 (18:0/18:1),	 indicating	that	a	hepatic	PPARδ-PC	
(18:0/18:1)-muscle	 PPARα signaling	 cascade	 coordinates	 fat	 synthesis	 and	 use.	 That	
PPARα	 ligands	are	products	of	 the	de	novo	synthesis	of	FA	 illustrates	a	 link	between	
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hepatic	 lipogenesis	and	peripheral	FAO.	This	 link	can	explain	how	tissues	 like	muscle	








The	 production	 of	 endogenous	 ligand	 of	 PPARa	 requires	 an	 esterification	 and	 re-
hydrolysis	cycle	 (Ong	et	al.	2011),	 suggesting	 that	 lipid	droplet	 (LD)	 formation	during	
the	fed-to-fasting	transition	could	be	necessary	for	PPARSYMBOL	
	activation.	 In	 vivo	 attenuation	 of	 liver	 ketogenesis	 (siRNA)	 downregulate	 FAO	 and	
Fgf21	expression	(Vilà-Brau	et	al.	2011a).	 In	this	model,	mRNA	analysis	 indicates	that	
Fsp27	 is	 one	 of	 the	 genes	 induced	 by	 liver	 knock	 down	 of	Hmgcs2	 (Vilà-Brau	 et	 al.	




(FSP27	 in	 mice)	 that	 were	 first	 identified	 by	 their	 sequence	 homology	 with	 the	 N	
terminal	 domain	 of	 the	 DNA	 fragmentation	 factor	 (DFF)	 and	 described	 as	 apoptosis	
activators.	 When	 transfected	 in	 adherent	 cells,	 they	 induce	 morphological	 changes,	
nuclear	condensation	and	fragmentation,	key	characteristics	of	apoptosis	 (Inohara	et	
al.	 1998).	 	 The	 CIDE	 proteins	 are	 essentially	 lipid	 droplet-associated	 proteins	 and	
important	regulators	of	lipid	storage	and	formation	of	lipid	droplets	in	adipocytes	and	
hepatocytes	but	their	roles	seem	to	be	more	complex	and	intricate	in	the	regulation	of	
lipid	 metabolism	 and	 be	 crucially	 involved	 in	 metabolic	 disorders,	 such	 as	 obesity,	
diabetes	mellitus,	liver	steatosis	and	cardiovascular	diseases	(Gong,	Sun,	and	Li	2009).	
















important	 regulator	 of	metabolic	 homeostasis	 and	 it	 is	 involved	 in	 the	 regulation	 of	
FAO	 (Matsusue	 et	 al.	 2008).	 Nowadays	 there	 are	 two	 isoforms	 of	 FSP27	 described:	
alpha	 and	 beta.	 FSP27α 	 (CIDEC1	 in	 humans)	 is	 mainly	 expressed	 in	 WAT,	 while	
FSP27β (CIDEC2)	 is	 expressed	 in	 steatotic	 and	 fasted	 livers	 but	 it	 also	 is	 the	
predominant	 isoform	 in	 brown	 adipose	 tissue	 (BAT).	 Concretely,	 Fsp27β	 is	 highly	
expressed	 in	 the	 livers	 of	 ob/ob	 and	 fasted	 mice	 while	 in	 WAT	 the	 predominant	
isoform	 is	 Fsp27α,	 both	 in	 wild-type	 and	 ob/ob	 mice	 (Xu	 et	 al.	 2015).	 Despite	 the	
specific	 tissue	 distribution	 between	 isoforms,	 a	 deficiency	 in	 these	 proteins	 leads	 to	
































liver	 Fsp27	 (Fsp27β)	 could	 be	 pharmacologically	 induced	 by	 PPARα	 ligands	 in	 liver	
(Langhi	 and	Baldán	 2014),	 despite	 its	 induction	 is	 not	 affected	 in	 starved	PPARα	 KO	





In	 summary	 Fsp27α	 promoter	 is	 regulated	 by	 C/EBP(Danesch,	 Hoeck,	 and	 Ringold	
1992),	 CREB	 (Vilà-Brau	 et	 al.	 2013)	 and	PPARγ (Matsusue	 et	 al.	 2008)	 in	WAT;	while	
Fsp27β	is	mainly	regulated	by	CREBH	in	liver	(Xu	et	al.	2015).		
	
Most	 of	 the	 data	 regarding	 Fsp27	 expression	 was	 obtained	 before	 knowing	 the	
existence	 of	 both	 isoforms.	 However,	 the	 strong	 tissue	 specific	 expression	 of	 both	









formed	 in	 the	 endoplasmic	 reticulum	 (ER),	 where	 enzymes	 catalyzing	 neutral	 lipid	
synthesis	(e.g.,	acyl-CoA	cholesterol	acyltransferases	(ACATs)	for	sterol	esters	and	acyl	
CoA:	 diacylglycerol	 acyltransferases	 (DGATs)	 for	 TGs)	 predominantly	 reside	 (Natalie	
Krahmer,	 Farese,	 and	 Walther	 2013).	 	 In	 fatty	 acid	 excess	 conditions,	 LDs	 rapidly	
increase	their	volumes,	as	seen	for	example	 in	cell	culture	or	murine	small	 intestine.	
During	LD	growth,	the	synthesis	of	neutral	lipids	and	phospholipids	is	coordinated:	as	
LD	 volume	 increases,	 surfaces	 expand,	 and	 phospholipids	 are	 needed	 to	 shield	 the	
neutral	 lipid	core,	reduce	surface	tension,	and	prevent	LD	collapse	(N.	Krahmer	et	al.	
2011).	 Thus,	 changes	 in	 LD	 phospholipid	 composition	 are	 important	 in	 determining	
their	morphology	and	may	play	a	role	in	diseases	with	altered	lipid	storage.	
	
Originally,	 FSP27	was	 thought	 to	be	uniquely	 involved	 in	 the	 formation	of	unilocular	
lipid	 droplets	 in	 WAT	 during	 adipogenesis,	 as	 its	 expression	 was	 highly	 increased	
during	this	process	(Puri	et	al.	2007;	Nishino	et	al.	2008).	Both	alpha	and	beta	isoforms	
of	 FSP27	 are	 localized	 around	 the	 LDs,	 and	 therefore	were	 thought	 to	 promote	 the	
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formation	 of	 large	 LDs,	 and	 suppress	 lipolysis.	 However,	 they	 differ	 in	 the	 first	 10	
amino	acids	 residues	 and	 shown	 tissue-specific	 distribution;	 therefore,	 it	was	expect	
that	they	might	vary	in	their	specific	functions.		
	
The	 LD	 size	 is	 variable	 and	 their	 growth	 is	 thought	 to	 occur	 by	 two	 different	
mechanisms:	the	first	one	is	the	growth	of	LD	itself	(as	mentioned	before),	the	second	
one	is	by	fusion	of	the	already	existence	LDs.	In	this	context,	full	 length	FSP27	seems	






an	 important	 issue	since	 it	can	determine	the	 fate	of	 the	accumulated	 fatty	acids.	 In	
WAT,	 FSP27α expression	will	 promote	 big	 unilocular	 lipid	 droplets	 that	 are	 ideal	 for	
efficient	 lipid	 storage	because	 lipolysis,	 from	 the	 LD	 surface,	 is	 restricted	due	 to	 the	
minimum	LD	surface	area.	 In	BAT,	FSP27β	expression	will	promote	small	multilocular	
















then	 down	 regulated	 during	 late	 fasting.	 Since	 CREBH,	 until	 now,	 is	 the	 only	 factor	
known	 to	 regulate	 Fsp27β	 expression,	 and	 CREBH	 is	 induce	 in	 both	 early	 and	 late	








Rev-Erbα 	is	 a	 nuclear	 receptor	 that	 participates	 in	 the	 clock	 circuitry	 and	 regulates	
lipid	metabolism,	 adipogenesis	 and	 vascular	 inflammation	 (Duez	 and	 Staels	 2008).	 It	
was	 considered	 an	 “orphan	 receptor”	 due	 to	 its	 lack	 of	 known	 ligands,	 until	 the	
porphyrin	 heme	 was	 demonstrated	 to	 function	 as	 a	 ligand	 for	 both	 REV-ERBα 	 and	
REV-ERBβ  (Duez	and	Staels	2008;	Burris	2008).		
	
REV-ERBα	 and	 REV-ERBβ lack	 the	 activation	 function-2	 region,	 associated	 with	 the	





The	 ligand	 heme	 modulates	 the	 activity	 of	 REV-ERB	 nuclear	 receptors,	 by	 binding	
directly	 to	 the	 ligand	binding	domain	 (LBD)	of	REV-ERB	and	 increasing	 its	affinity	 for	
the	 corepressor	 NCoR	 (Figure	 I8).	 This	 complex	 will	 lead	 to	 gene	 repression	 due	 to	
histone	 deacetylase	 activity	 from	 the	 nuclear	 receptor	 co-repressor	 (NCoR)/histone	
deacetylase	complex	(Burris	2008).	
	
Modulation	 of	 clock	 and	metabolism	by	 Rev-Erbα	 is	 accomplished	 through	 different	
pathways.	 To	 regulate	 clock	 control	 genes,	 it	 binds	 directly	 to	 the	 genome	 at	 its	
cognate	sites	competing	with	activating	ROR	transcription	factors;	on	the	other	hand,	
to	regulate	metabolic	genes	it	works	by	recruiting	the	histone	deacetylase	3	(HDAC3)	






More	 recently,	 it	 was	 described	 that	 REV-ERB〈 works	 cooperatively	 with	 the	





Thus,	 HNF6	 regulates	 hepatic	 lipid	metabolism	 in	 adult	 livers	 through	 a	mechanism	
that	 involves	 the	 HNF6-dependent	 tethering	 of	 REV-ERBα.	 Together	 they	 repress	 a	


















































The	 cells	 were	 cultured	 in	 a	 1:1	mixture	 of	 Dulbecco’s	Modified	 Eagle	Medium	 and	
Ham’s	F12	medium(DMEM:F12,	supplemented	with	0,005	mg/ml	insulin,	0,005	mg/ml	
transferrin,	 5	 ng/ml	 selenium,	 40	 ng/ml	 dexamethasone,	 4	 mM	 glutamine,	 100	
units/ml	 penicillin	 G,	 100ug/ml	 streptomycin,	 and	 heat-inactivated	 10%	 (v/v)	 Fetal	
Bovine	Serum	(FBS).	
	
The	HepG2	 (human	 liver	 carcinoma)	 cell	 line	was	 derived	 from	 the	 liver	 tissue	 of	 a	
fifteen	 years	 old	 male	 with	 differentiated	 hepatocellular	 carcinoma.	 These	 cells	 are	
adherent,	epithelial-like,	growing	as	monolayers	and	in	small	aggregates.	
The	 cells	were	 cultured	 in	Eagle’s	Minimum	Essential	Medium	 (MEM)	 supplemented	
with	 4	 mM	 glutamine,	 100	 units/ml	 penicillin	 G,	 100ug/ml	 streptomycin,	 and	 10%		
(v/v)	Fetal	Bovine	Serum	(FBS).	
	
The	HEK-293A	 cell	 line	 is	 a	 subclone	 of	 the	HEK-293	 (human	 embryonic	 kidney)	 cell	
line.	 Its	 relatively	 flat	morphology	 facilitates	 the	 initial	 production,	 amplification	 and	









The	 cells	 were	 incubated	 at	 37oC	 in	 a	 humidified	 atmosphere	 containing	 5%	 CO2.	


















































with	 the	 restriction	enzyme	EcoRV,	 and	has	additional	3’	 terminal	 thymidine	at	both	






the	 lacZ	 gene	 and	 the	 β-galactosidade	 activity.	 In	 a	 medium	 supplemented	 with	
ampicillin	 (100mg/L),	 IPTG	 (	8	mg/L)	and	X-Gal	 (	40	mg/L),	 the	 recombinant	 colonies	
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upstream	 of	 the	 LUC	 gene.	 It	 does	 not	 have	 a	 eukaryotic	 promoter,	 or	 enhancer	
sequences;	 therefore	 the	 activity	 of	 the	 luciferase	 enzyme	 in	 the	 transfected	 cells	 is	
dependent	on	the	activity	of	the	inserted	promoter,	object	of	study.	
	















The	 sequences	 and	 orientations	 of	 the	 constructions	 were	 verified	 by	 sequencing	
(Macrogen	sequencing	service).	
	
The	 Fsp27β promoter	 (-900,	 +76,	 relative	 to	 +1β)	was	 amplified	by	PCR	 from	mouse	
genomic	DNA	using	 sequence	 specific	 oligonucleotides	 (table	 1)	 and	 cloned	 into	 the	
pGL3-basic	vector	(Promega),	using	the	restriction	sites	Xho	and	MluI.		
The	 Fsp27	 promoter	 including	 both	 α	 and	 β	 isoforms	 (Fsp27αβ-	 pGl3b)	 (-2024	 to	
+1013,	 relative	 to	 +1α),	 was	 amplified	 by	 PCR	 from	 mouse	 genomic	 DNA	 using	













Fsp27α	 cDNA	 was	 amplified	 by	 PCR	 from	 mouse	 cDNA	 using	 sequence	 specific	




















Mouse	 PPARα	expression	 vector	 (PPARα-pSG5)	was	 a	 gift	 from	 Dr.	 S.	 Green,	
Maclesfield.	
The	 thymidine	 kinase	 promoter	 under	 the	 control	 of	 three	 PPRE	 elements	 ((PPRE)3-
Tkluc)	was	a	gift	from	Dr.	F.Villaroya.	
Human	 RevErbα	 expression	 vector	 (pSG5-hRevErba)	 and	 human	 RORa1	 expression	
vector	(pSG5-RORa1)	and	was	a	gift	from	Dr.	J.C.	Rodríguez.	
	
























were	 co-transfected	 with	 400	 ng	 of	 the	 reporter	 gene	 construct	 (Fsp27β-pGl3b	 or	



















































































48h	 after	 the	 infection	 the	 cells	 were	 observed	 in	 a	 fluorescence	 microscope	 (the	
adenovirus	 expressed	 the	 green	 fluorescence	 protein)	 and	 the	 green	 cells	 were	
counted.		

























For	 the	 comparison	 of	 Fsp27β	 expression	 between	 the	 fed	 and	 fasted	 state,	 with	 a	
































Mice	 serum	 was	 obtained	 by	 clotting	 whole	 blood	 (30	 minutes,	 RT)	 following	 a	







Serum	 samples	 were	 diluted	 with	 PBS	 followed	 by	 a	 liquid/liquid	 extraction	 with	
methanol	 and	 a	 solution	 of	 the	 internal	 standard	 (16:0D31-18:1	 PC)	 in	 chloroform	
(final	 concentrations	of	 PBS:	MeOH:	CHCl3	were	 1:1:2).	 The	mixture	was	 thoroughly	
vortexed	 and	 then	 centrifuged	 at	 10,000	 rpm	 to	 provide	 two	 liquid	 phases	 (one	
aqueous	 layer	on	the	top	and	an	organic	 layer	at	the	bottom)	separated	by	a	disk	of	
white	 solid	 material.	 An	 aliquot	 of	 the	 lipid-containing	 layer	 (organic	 phase)	 was	
evaporated	 to	 dryness	 using	 a	 constant	 stream	 of	 nitrogen	 and	 re-dissolved	 in	
hexane/methyl-tert-butyl-ether	 (MTBE)/acetic	 acid	 (100:3:0.3)	 followed	 by	
fractionation	using	a	column	purification	method,	as	described	(24).	Briefly,	Bond	Elut	
SS-NH2	 cartridges	 (3	ml,	 500	mg,	 47-60	mm,	Varian)	were	equilibrated	3	 times	with	
acetone/water	(7:1)	and	washed	with	two	1	ml	portions	of	hexane.	Lipids	were	loaded	
onto	 the	 column	 and	 were	 eluted	 sequentially	 with	 hexane,	 hexane/CHCl3/AcOEt	
(100:5:5),	 CHCl3/iPrOH	 (2:1),	 CHCl3/MeOH/AcOH	 (100:2:2)	 and	 finally	 the	
phospholipid	 fraction	 was	 eluted	 with	 CHCl3/MeOH/H2O	 (5:10:4),	 evaporated	 to	







The	HPLC	 system	consisted	of	 an	Agilent	1290	 Infinity	 (Waldbronn,	Germany)	 binary	
pump	 equipped	 with	 a	 thermostated	 (10	 °C)	 autosampler.	 For	 the	 analysis	 of	 the	
extracts,	a	Mediterranea	Sea	C18	column	(100	×	2.1	mm,	2.2	μm)	(Teknokroma)	was	
used,	 mantained	 at	 50	 °C.	 Mobile	 phase	 A	 consisted	 of	 95:5	 water:methanol	 and	
mobile	phase	B	was	composed	of	60:35:5	 isopropanol:methanol:water.	Both	A	and	B	
were	 supplemented	with	0.1%	 formic	 acid	 and	5	mM	ammonium	 formate.	 The	 flow	
rate	was	0.5	ml	min-1	and	the	injection	volume	2	μl.	A	linear	gradient	profile	with	the	
following	proportions	of	solvent	B	was	applied	(t,	%B):	 (0,	20),	 (5,	20),	 (20,	100),	 (25,	
100),	(26,	20),	(35,	20).	MS/MS	experiments	were	performed	on	an	QTRAP	6500	mass	
spectrometer	(AB	SCIEX,	Concord,	Ontario,	Canada).	All	the	analyses	were	performed	
using	the	 IonDrive™	source	 in	positive	 ion	mode	with	the	following	settings:	capillary	
voltage	5500	V,	temperature	500	ºC,	curtain	gas	(N2)	25	(arbitrary	units),	GS1	(N2)	50	
(arbitrary	units),	GS2	 (N2)	30	 (arbitrary	units),	 collision	gas	Medium	 (arbitrary	units),	
declustering	potential	(DP,	Table	3),	entrance	potential	10	V,	collision	energy	(CE,	Table	
3),	 collision	 cell	 exit	 potential	 (CXP,	 Table	 3).	 All	 the	 MS/MS	 parameters	 were	
optimized	in	infusion	experiments:	individual	standard	solutions	of	18:0-18:1	PC,	16:0-
18:1	PC	and	16:0D31-18:1	PC	(100	ng	μl−1)	were	infused	at	a	constant	flow	rate	of	5	μl	
min−1	 into	 the	mass	 spectrometer.	 Relative	 quantification	 of	 phosphocoline	 species	
was	 done	 using	 stable	 isotope	 dilution	 mass	 spectrometry	 with	 the	 spectrometer	













16:0-18:1	PC	 760.6/184.1	 171	 39	 16	
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Lipids	 from	 the	 livers	of	mice	were	extracted	with	5%	NP40/ddH2O	and	TG	 levels	 in	






Frozen	 tissues	were	 chopped	 in	 liquid	 nitrogen	 and	 crushed	 in	 TRI	 Reagent	 solution	
with	 the	 help	 of	 a	 politron	 and	 the	 RNA	 was	 isolated	 following	 the	manufacturer’s	
instructions.	
The	 RNA	 was	 pre	 treated	 with	 DNAse	 I	 (Ambion)	 to	 eliminate	 genomic	 DNA	
contamination	and		
dissolved	 in	 DEPC-water	 (Sigma-Aldrich)	 and	 the	 concentration	 and	 purity	 of	 each	
sample	 was	 obtained	 from	 A260/A280	 and	 A260/A230	 measurements	 in	 a	 micro	









One	 microgram	 of	 total	 RNA	 was	 used	 to	 synthesize	 the	 cDNA	 by	 M-MLV	 reverse	
transcriptase	 (Invitrogen)	 with	 random	 hexamers	 (Roche	 Diagnostics)	 and	 dNTPs	
(Attend	Bio)	according	to	manufacturer’s	instructions.		
The	 SYBR	 Green	 PCR	 Master	 Mix	 and	 Taqman	 Gene	 Expression	 Master	 Mix,	 was	
supplied	by	Applied	Biosystems	(ThermoFisher	Scientific)	and	used	for	the	PCR	step.	





















Fsp27α 	 GCCACGCGGTATTGCCAGGA	 TCCATGCGGTAATATGCTT	























































Fsp27	 is	 a	 response	 gene	 in	 the	 fasted	 liver,	 it	 has	 a	 particular	 expression	 pattern,	
showing	 changes	 in	 liver	during	 the	 fasting	period	by	 increasing	at	 the	beginning	 (6-
15h)	and	lowing	in	the	long	fasting	(24h)	(Vilà-Brau	et	al.	2013).	For	this	reason,	it	was	
important	 to	 study	 the	mechanisms	underlying	 this	 regulation,	 as	 explained	 in	more	
detail	below.	
	
1.1 	Expression	pattern	of	Fsp27α 	and	Fsp27β 	in	different	tissues			
Two	different	isoforms	(FSP27α	and	FSP27β),	differing	in	the	first	10	amino	acids	and	
driven	by	different	promoters	are	expressed	from	the	same	gene	(Xu	et	al.	2015).	 In	
order	 to	 compare	 the	mRNA	 expression	 of	 both	 isoforms	 in	 different	 tissues	 under	
































































































































































































In	 2013,	 our	 group	described	 the	hepatic	 expression	pattern	of	Fsp27	during	 fasting	





Fsp27β	 and	Fsp27α	mRNA	 levels	were	measured	 in	 livers	of	 fasted	mice	at	different	
time	 points	 (0,	 6,	 15	 and	 24	 hours).	 As	 figure	 R	 2	 shows,	 Fsp27β	 has	 the	 same	
expression	pattern	as	total	Fsp27	(Vilà-Brau	et	al.	2013).	As	the	mRNA	of	alpha	isoform	


























































































































To	 study	 its	 importance	 in	 the	 adaptation	 to	 fasting	 and	 thus	 have	 a	 better	
understanding	of	FSP27	expression	pattern,	its	transcriptional	regulation	was	studied.	
Globally	the	experimental	approach	used	to	solve	this	part	of	the	work	was	based	on	
transient	 transfection	 assays.	 A	 hepatic	 cell	 line	 model	 (AML12)	 was	 used	 to	 co-
transfect	 luciferase	 reporter	 constructs	 that	 include	 different	 regions	 of	 the	 Fsp27	








up	 regulated	 in	an	early	 fasting	and	down	regulated	 in	a	 late	 fasting.	As	 for	 the	 first	
part	of	the	question,	the	proposed	responsible	for	the	up-regulation	of	Fsp27β	 is	the	
transcription	 factor	 Cyclic-AMP-responsive-element-binding-protein	 H	 (CREBH).	 For	
the	 second	 part,	 lower	 induction	 in	 late	 fasting,	we	 proposed	 either	 the	 acetylation	
levels	of	CREBH	or	Rev-Erbα expression.	







Figure	R	4.	CREBH	and	Rev-Erbα 	are	possible	Fsp27β 	regulators	(A)	CREBH	and	(B)	Rev-Erbα  gene	expression	in	
the	livers	of	fasted	mice,	at	different	time	periods	(black	bars:	Ad	Libitum,	white	bars:	6	hours	fasting,	light	grey	
bars:	15	hours	 fasting,	dark	grey	bars:	24	hours	 fasting).	Error	bars	 represent	 the	mean	±standard	error	of	 the	
mean	(SEM)	*	p<	0,05	and	**p<	0,01	relative	to	expression	Ad	Libitum.			
In	figure	R	4A,	the	CREBH	mRNA	expression	is	induced	constantly	during	the	course	of	
the	 fasting	 period,	 therefore	 showing	 an	 up-regulation	 in	 fasting	 state.	 As	 for	 Rev-
Erbα, its	expression	pattern	shown	in	figure	R	4	B	 illustrates	that	 its	mRNA	levels	are	

















































































levels	 are	 regulated	 by	 different	 signals	 and	 transcription	 factors.	 Looking	 for	 the	





marked	 in	 figure	 R	 5,	 along	 with	 the	 Fsp27α	 transcription	 starting	 site	 (+1α)	 and	
Fsp27β	transcription	starting	site	(+1β).		
	













gene	 expression	 were	 used	 (Figure	 R6).	 The	 Fsp27αβ construct	 (-2024	 to	 +1013	
relative	 to	 +1α) includes	 both	 transcription	 starting	 sites	 (+1α	 and	 +1β)	 and	 the	





elements	 that	 control	 Fsp27β	 expression	 various	 constructs	 with	 different	 deletions	









2.2 	Fsp27β 	is	a	CREBH	but	not	a	PPARα 	target	gene			
As	 stated	 above,	 there	 is	 a	 CHRE	 site,	 a	 CREBH	 response	 element	 in	 the	
Fsp27β promoter,	and	consequently	CREBH	is	an	activator	of	the	alternative	β	isoform.	
The	 promoter	 sequence	 described	 for	 Fsp27α contains	 a	 PPRE	 element,	 that	 is	 not	
present	 in	 the	 specific	 promoter	 sequence	 for	 the	β	 isoform.	 In	 order	 to	 study	 the	
effects	of	both	CREBH	and	PPARα in	the	regulation	of	Fsp27,	the	Fsp27β promoter	was	
co-transfected	 in	 AML12	 cells	 with	 CREBH	 and	 PPARα (Figure	 R	7A).	 Although	 the	





900,+76	 relative	to	 +1β),	 (D)	Fsp27β (-584,+76	 relative	to	 +1β),	 (E)	Fsp27(-300,	+76	relative	 to	+1β)	and	(F)	
Fsp27β 	(-90,	+76	relative	to	+1β )	,	CREBH	response	element	(-35,-	24	relative	to	+1β ).	
RESULTS	
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The	mutant	 K294Q	 showed	 similar	 effects	 as	 the	wild-type	 CREBH	Nuclear,	 and	 the	
K294R	acetylation	deficient	mutant	K294R	failed	to	induce	Fsp27β in	the	same	extent.	
	















































cells	 were	 co-transfected	 with	 the	 Fsp27β	 promoter,	 CREBH	 and	 REV-ERBα. In	












Moreover,	 both	 the	 Fsp27αβ	 and	 the	 Fsp27β	 promoter	 were	 co-transfected	 with	







































Figure	R	9.	Fsp27αβ 	 regulation	 through	CREBH	and	REV-ERBa.	Fsp27β 	promoter	 (-900	to	+76,	 relative	to	









Based	 on	 the	 results	 that	 indicate	 that	 REV-ERBα	 is	 not	 a	 direct	 repressor	 of	 the	
Fsp27β	 promoter	 and	 knowing	 that	 REV-ERBα	 works	 cooperatively	 with	 the	
transcription	 factor	 HNF6	 to	 regulate	 the	 hepatic	 lipid	 metabolism	 (Y.	 Zhang	 et	 al.	
2016a)	 AML12	 cells	 were	 co-transfected	 with	 the	 Fsp27β	 promoter	 and	 the	 HNF6	

















































































With	 this	 result,	 the	 next	 step	 was	 to	 map	 the	 HNF6	 putative	 binding	 site,	 that	 is	
predicted	to	be	at	-155	to	-141	relative	to	+1β, performing	deletions	of	the	promoter	
as	 detailed	 previously	 (Figure	 R	 6).	 The	 different	 constructs	 (Fsp27β(-584),	 Fsp27β(-
300)	and	Fsp27β(-90))	were	transfected	in	AML12	cells	with	or	without	HNF6,	as	seen	
in	figure	R	13	A,B	and	C,	respectively.	In	figure	R	13C,	the	shorter	promoter	construct,	




test	 the	 effect	 of	HNF6,	 by	 co-	 transfecting	 different	 amounts	 of	 CREBH	and	 a	 fixed	















































Finally	 and	 looking	 for	 the	 role	 of	 REV-ERBα we	 analyzed	 the	 results	 of	 a	 ChIPseq	
experiment	published	by	Mitchell	Lazar’s	group	(GSM1659686).	They	used	livers	from	
129S1/SvlmJ	 mice	 to	 extract	 protein	 and	 performing	 the	 chromatin	
immunoprecipitation	with	a	REV-ERBα antibody. After	After	 the	 immunoprecipitation	























































































































Figure	R	12.	HNF6	affects	FSP27β 	regulation,	through	CREBH.	 (A)	Fsp27β (-584)	(-584	to	+76,	 relative	to	+1β),	
(B)	Fsp27β (-300)	(-300	to	+76,	relative	to	+1β ),	(C)	Fsp27β(-90)	(-90to	+76,	relative	to	+1β)	activity	in	AML12	
cells	co-transfected	with	the	transcription	factors	HNF6	and	CREBH	co-transfected	with	the	same	amount	of	each	


















clearly	understood.	While	PPARα	 is	 activated	 in	 feeding	periods,	and	not	by	adipose	
stores	 (Chakravarthy	 et	 al.	 2005),	 its	 target	 genes	 are	 expressed	 in	 fasting	 but	 its	
expression	is	impaired	when	FASN	is	absent	(FASKOL).	Nowadays	two	phosphocholines	
(16:0/18:1	 and	18:0/18:1)	 has	been	described	as	 PPARα	 ligands	 (Chakravarthy	 et	 al.	
2010)(S.	 Liu	et	 al.	 2013).	 Therefore,	 this	may	uncover	a	 link	between	Fsp27,	with	 its	













3.1 Interference	of	PPARα 	signaling	by	Fsp27β 	in	vitro	
	
For	the	first	approach,	a	hepatic	cell	line	model	(HepG2)	was	used	to	transfect	the	TK	





















To	 evaluate	 the	 role	 of	 FSP27β	 expression	 in	 PPAR	 signaling	 in	 vivo,	 its	 hepatic	
expression	 was	 knocked-down	 in	 fed	 and	 starved	 animals,	 by	 using	 an	 adenovirus-
mediated	 shRNA.	 The	mice	were	divided	 in	 two	different	 groups,	 the	 control	 group,	
with	 a	 shRNA	 control	 adenovirus	 and	 the	 shFSP27	 group,	 with	 a	 shRNA	 silencing	
FSP27.		
	
The	 experiment	 was	 conducted	 in	 two	 different	 conditions,	 Ad	 Libitum,	 and	 at	 17	
hours	fasting.	This	time	frame	was	chosen	by	combining	the	Fsp27	expression	pattern	































As	 expected,	 there	 is	 an	 increase	 in	 the	expression	of	 the	hepatic	Fsp27β	 in	 fasting,	
concomitant	with	Fsp27	pattern	of	expression	in	this	condition	(Vilà-Brau	et	al.	2013),	
relative	to	the	control	ad	libitum	mice.	In	both	conditions,	there	is	a	significant	down-








FSP27	 affects	 the	 expression	 of	 genes	 like	 Fgf21	 and	Hmgcs2	 (Figure	 R	 17A	 and	 B,	
repectively)	,	showing	that	their	induction	in	fasting	is	dependent	on	Fsp27	expression.		
	
































Figure	R	15.	Successful	Fsp27β 		hepatic	knockdown.	Fsp27β  gene	expression	in	the	livers	of	mice	fed	Ad	Libitum	


















































































































Figure	R	 16.	 Effects	 of	 hepatic	 Fsp27β 	 knockdown	 in	 liver.	 Gene	 expression	 in	 the	 livers	 of	mice.	 (A)	 Fgf21,	 (B)	





















phospholipids	 was	 lower	 in	 fasted	 animals	 in	 comparison	 with	 the	 fed	 animals.	
Nonetheless,	 in	 the	 animals	 lacking	 hepatic	 Fsp27β,	 the	 levels	 of	 phospholipids	 in	
serum	 are	 higher,	 in	 both	 conditions	 (Figure	 R	 18).	 These	 two	 results	 put	 together	
suggest	 that	 Fsp27β	 expression	 is	 essential	 to	 accommodate	 TAG	 in	 liver	 and	 to	
preserve	the	phospholipids	needed	for	the	formation	of	the	lipid	droplets.	
CTL	 ShFsp27	 CTL	 ShFsp27	
Ad	Libitum	 Fasted	17h.	




































Figure	 R	 17.	 Fsp27	 hepatic	 knockdown	 alters	 TAG	 levels.	 (A)	 Serum	 levels	 (mg/dL)	 and	 (B)	 liver	 levels	 (mg/g	
tissue)	of	 TAG.	Mice	were	 fed	Ad	 Libitum	or	 fasted	 for	 17	hours	treated	with	 shRNA	 control	 adenovirus	 (CTL:	













The	 increase	 in	 the	 levels	 of	 phospholipids	 in	 serum	 of	 Fsp27β	 knockdown	 animals	
(Figure	R	18)	correlates	with	a	decrease	in	PPARα	 late	fasting	responsive	genes,	such	
as	Fgf21	and	Hmgcs2	(Fig	16).	Therefore,	it	is	possible	that	endogenous	PPARα	ligands	
are	 being	 secreted	 from	 the	 liver,	 losing	 lipid	 droplet	 formation	 capacity.	 To	 further	
study	 the	 implications	 of	 the	 absence	 of	 Fsp27β	 in	 liver,	 the	 expression	 pattern	 of	
PPARα	target	genes	were	also	studied	in	BAT	and	muscle	(Figure	R	19).	
CTL	 ShFsp27	 CTL	 ShFsp27	
Ad	Libitum	 Fasted	17h.	
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phosphocholine	 (PC	 16:0/18:1).	Mice	were	 fed	Ad	 Libitum	or	 fasted	 for	 17	 hours	 treated	with	 shRNA	 control	
adenovirus	(CTL:	white	or	dark	grey	bars,	respectively)	or	shFsp27	specific	adenovirus	(shFSP27:	light	dark	or	dark	









CTL	 ShFsp27	 CTL	 ShFsp27	
Ad	Libitum	 Fasted	17h.	


















































































































































mice	 fed	Ad	Libitum	or	 fasted	for	17	hours	treated	 	with	shRNA	control	adenovirus	 (CTL:	white	or	dark	grey	
bars,	 respectively)	 or	 shFsp27	 specific	adenovirus	 (shFSP27:	 light	dark	or	dark	respectively).	 (A-E)	BAT	Ucp1,	
Fgf21,	Cpt1b,	Cpt2,	Fsp27b,	respectively.	 (F)	Muscle	Cpt1b.	Error	bars	represent	the	mean	±standard	error	of	



























































































identified	 that	 these	 compounds	 bound	 to	 a	 nuclear	 receptor	 that	 was	 known	 as	
peroxisome	proliferator	activated	receptor	(PPAR).	
	
We	now	know	 that	 the	endogenous	 ligands	of	PPAR	are	 the	 fatty	acids,	or	products	
derived	 from	 them	 like	 certain	 prostaglandins.	 PPARs	 are	 the	way	 to	 regulate	 gene	
expression	according	to	the	availability	of	fatty	acids.	
The	 three	PPARs,	PPARα,	 PPARβ/δ	 and	PPARγ,	 show	distinct	 tissue	distributions	and	
regulate	 various	 aspects	 of	 lipid	metabolism.	 The	 best-described	 functions	 for	 these	
receptors	 include	 the	 adipogenic	 and	 insulin-sensitizing	 effects	 of	 PPARγ	 and	
regulation	of	fatty	acid	catabolism/mitochondrial	oxidative	metabolism	by	PPARα	and	
PPARδ	 in	 liver	 and	 muscle,	 respectively.	 In	 the	 liver,	 PPARα	 and	 PPARδ	 exhibit	
opposing	activities	in	the	control	of	diurnal	lipid	metabolism.	PPARα is	up-regulated	in	
the	fasted	state	to	regulate	fat	catabolism	(Kersten	et	al.	1999).	By	contrast,	PPARδ	is	
more	 active	 in	 the	 fed	 state	 and	 controls	 the	 transcription	 of	 lipogenic	 genes	
(Sanderson	et	al.	2010;	S.	Liu	et	al.	2011;	S.	Liu	et	al.	2013).	
	
The	most	 important	 contribution	 to	 identify	 the	 endogenous	 ligands	 of	 PPARα	 was	
made	in	the	FASKOL	animal	model	(Chakravarthy	et	al.	2005).	This	animal	is	unable	to	
synthesize	 fats,	 and	 when	 fed	 with	 a	 zero	 fat	 diet	 and	 subjected	 to	 fasting,	 is	
hypoglycemic.	 In	 fact,	 this	 model	 shows	 a	 phenotype	 similar	 to	 a	 fasted	 PPARα	
knockout	 animal.	 By	 pharmacologically	 activating	 PPARα 	 in	 the	 FASKOL	mice,	 these	
effects	 were	 reversed.	 Thus,	 it	 can	 be	 said	 that	 metabolic	 abnormalities	 in	 FASKOL	
mice	are	driven	by	the	failure	to	activate	PPARα	(Chakravarthy	et	al.	2005).	
	
Therefore,	 in	 the	absence	of	dietary	 fat,	 FAs	 synthesized	de	novo	 through	FAS	 (fatty	
acid	 synthase)	are	able	 to	act	 as	PPARα ligands	 (Chakravarthy	et	 al.	 2005).	 Later	on,	
the	 phospholipid	 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine	 (16:0/18:1	 GPC)	









inducing	 the	 expression	 of	 PPARα-dependent	 genes	 and	 affecting	 lipid	
metabolism(Chakravarthy	et	al.	2010).	
	
However,	 this	model	 generates	 a	 new	 paradox	 in	 the	 PPAR	 field.	 The	 expression	 of	
PPARα	 is	 circadian	 (Lemberger,	Desvergne,	 and	Wahli	 1996),	with	a	decrease	of	 this	
receptor	 protein	 in	 the	 fed	 state	 and	 an	 increase	during	 fasting,	 coinciding	with	 the	
need	 for	 FA	 oxidation	 to	 maintain	 the	 energy	 balance.	 Since	 the	 16:0/18:1	 GPC	
production	and	peak	of	PPARα	 activity	are	anti-phasic,	 it	 could	be	postulated	 that	 if	
FAS	is	essential	for	producing	the	PPARα	ligand,	then	additional	regulation	is	required	
to	present	the	ligand	to	PPARα	when	needed.	In	this	Thesis,	we	are	proposing	that	this	







PPARδ	 shows	 an	 ubiquitous	 pattern	 of	 expression.	 In	 muscle	 it	 is	 attributed	 a	
fundamental	 role	 in	 the	 regulation	 of	 mitochondrial	 fatty	 acid	 oxidation.	 Thus,	





However,	 in	 liver,	 PPARδ plays	 a	 lipogenic	 role	 as	 indicated	 by	 overexpression	
(adenovirus)	experiments	(S.	Liu	et	al.	2011)	or	knockout	animal	models(C.-H.	Lee	et	al.	
2006).	Recently,	it	has	been	shown	that	PPARδ	controls	diurnal	expression	of	lipogenic	




activity.	 Interestingly,	 18:0/18:1-GPC	 reduces	 postprandial	 lipid	 levels	 and	 increases	
fatty	acid	use	through	muscle	PPARα	(S.	Liu	et	al.	2013).		
	
PPARδ	expression	 peaks	 at	 night	 parallel	 to	 the	mRNA	 levels	 of	 the	molecular	 clock	
Bmal1	in	the	liver.	Therefore,	it	is	feasible	that	hepatic	PPARδ  alters	the	expression	of	
muscle	 genes	 and	 FA	 use	 through	 PC	 (18:0/18:1),	 indicating	 that	 an	 hepatic	 PPARδ-
PC(18:0/18:1)-muscle	PPARα signalling	cascade	coordinates	fat	synthesis	and	use.	
	
That	 PPARα	 ligands	 are	 products	 of	 the	 de	 novo	 synthesis	 of	 FA	 illustrates	 a	 link	
between	hepatic	lipogenesis	and	peripheral	FAO.	This	link	can	explain	how	tissues	like	
muscle	oxidize	fatty	acids,	depending	on	circadian	hepatic	synthesis,	at	specific	times	
coinciding	 to	 the	animal	activity.	However,	as	mentioned	before,	 the	 requirement	of	




During	 periods	 of	 fasting,	 the	 liver	 needs	 to	 adapt	 its	 metabolism	 to	 maintain	 the	
production	 of	 glucose	 and	 keep	 a	 state	 of	 normoglycemia.	 Gluconeogenesis	 takes	
action	when	the	reducing	power	(NADH)	is	made	available	through	the	mitochondrial	
oxidation	of	FAs	mobilized	 from	WAT	during	 fasting	 (McGarry	and	Foster	1995).	The	
liver	synthesizes	ketone	bodies,	which	are	soluble	products	of	incomplete	oxidation	of	





Brau	 et	 al.	 2013).	More	 relevant,	 ketogenesis	 is	 needed	 to	maintain	 the	β-oxidation	
flux	of	fatty	acids,	probably	because	releases	free	CoA	from	the	acyl-CoA	allowing	the	
activation	 of	 new	 acyl	 molecules.	 In	 agreement,	 Hmgcs2,	 the	 gene	 that	 controls	





Seeking	 for	 new	 mechanisms	 involved	 in	 liver	 gene	 expression	 during	 starvation,	 a	
microarray	 was	 performed	 to	 compare	 the	 expression	 pattern	 of	 wild	 type	 with	
HMGCS2	 knockdown	 animals.	 One	 of	 the	 genes	 that	 was	 up	 regulated	 when	
ketogenesis,	 and	 therefore	 FAO,	 was	 blocked	 was	 Fsp27β/CIDEC.	 Similar	 result	 was	





fasting	 but	 over	 longer	 periods	 of	 fasting	 (15-24	 h),	 the	 expression	 of	 Fsp27β	
decreases.	 FSP27	 is	 as	 a	 lipid-droplet	 formation	 protein,	 and	 its	 induction	 during	
fasting	was	unexpected.	Nonetheless,	in	humans	more	than	60%	of	the	FAs	that	reach	
the	liver	during	fasting	are	re-esterified	(Kalhan	et	al.	2001)	and	a	futile	cycle	of	TG/FA	






also	 the	 endogenous	 phospholipids	 needed	 for	 the	 LDs	 generation.	 In	 concordance,	
Fsp27β	expression	drops	when	PPARα	target	genes	are	robustly	expressed	(>	15	h	of	









1)	 If	 the	 peculiar	 pattern	 of	 Fsp27β	 expression	 in	 liver	 plays	 a	 role	 in	 PPARα	
signaling	by	accumulating/liberating	specific	endogenous	ligands.	




objective	 since	 FSP27β	 is	 the	 main	 form	 expressed	 in	 liver	 (Figure	 1	 and	 (Xu	 et	 al.	
2015)).	However,	it	affects	our	strategy	of	studying	the	role	of	FSP27β	in	liver.	A	floxed	
mouse	line	was	generated	in	which	the	first	loxP	site	was	introduced	in	the	first	intron	
of	 the	 Fsp27	 gene	 (Tanaka	 et	 al.	 2015),	 before	 discovering	 that	 Fsp27	 gene	 has	 an	
alternative	promoter	that	drives	the	expression	of	β	isoform	(Xu	et	al.	2015).	Sequence	
of	the	floxed	allele	(A.	Baldan,	personal	communication)	shows	that	the	loxP	sequence	
disturbed	 the	 CREBH	 element,	 present	 upstream	 of	 exon	 1B,	 that	 is	 essential	 for	 it	
expression	(Figures	6-8	and	(Xu	et	al.	2015)),	therefore	this	animal	has	down	regulated	
the	 CREBH-dependent	 Fsp27β	 expression	 in	 all	 tissues	 and	 was	 discarded	 for	 this	
study.	
	
Therefore,	 we	 decided	 to	 use	 adenovirus-mediated	 interference,	 to	 acute	 down	
regulate	Fsp27β	expression	 in	 liver	of	fasted	animals,	and	study	the	effect	of	 iRNA	in	








steatosis	 induced	 by	 fasting	 (Figure	 R	 17B).	 Importantly,	 liver	 Fsp27β	 expression	
appears	also	important	for	TAG	accumulation	in	liver	under	feeding	conditions	(Figure	
R	17B).	Fasting	reduces	the	analyzed	GPC	in	serum,	but	in	the	animals	lacking	hepatic	
Fsp27β,	 the	 phospholipids	 in	 serum	 are	 higher	 (Figure	 R	 18).	 Therefore,	 despite	 the	
role	of	Fsp27β	 in	 liver	 lipid	droplet	 formation,	 this	 result	 encouraged	 the	analysis	of	
PPARα-target	 gene	expression	 in	 liver	and	extrahepatic	 tissues,	 since	 it	 appears	 that	
PPARα	ligands	are	overflowing	in	a	liver	that	lacks	Fsp27β	expression.	It	is	important	to	
note	that	in	untreated	animals,	fasting	induces	serum	TAG	(Figure	R	17A)	but	reduced	









2013).	 This	 observation	 reinforces	 our	 proposed	 model	 for	 PPARα	 signaling	 during	







and	Baldán	2014)).	 The	 induction	of	Fsp27β	 in	BAT	 (Figure	R	17E)	 indicates	 that	our	
adenovirus	 specifically	 targets	 the	 liver	 of	 treated	 animals	 and	 hits	 inside	 the	 open	
debate	about	 if	Fsp27	 is	a	PPARα	 target	gene.	Others	(Matsusue	et	al.	2008)	and	we	
(Vilà-Brau	et	al.	2013)	have	indicated	that	liver	expression	of	Fsp27β	is	not	dependent	




no	 induction	by	 fasting	was	observed	 in	a	PPARα knock	out	mice	(Langhi	and	Baldán	
2014).	The	 result	 shown	here	 (Figure	R	17E)	could	somehow	conciliate	contradictory	
data,	since	appears	that	Fsp27β	could	be	a	target	of	PPARα	in	extrahepatic	tissues.		
	
As	 so,	 the	 induction	 of	 PPARα	 signaling	 in	 BAT,	 during	 lack	 of	 hepatic	 Fsp27β	




an	 obviously	 impact	 regarding	 our	 second	 of	 our	 objective	 in	 this	 Thesis,	 the	
mechanism	 that	 controls	 Fsp27β	 expression	 during	 early	 and	 late	 fasting.	 In	 the	
putative	 role	 of	 the	 Fsp27β	 on	 PPARa	 signaling	 could	 be	 important	 the	 induction	




two	 temporally	 phases	 separated	 by	 the	 status	 of	 SIRT1	 activation	 (Dominy	 et	 al.	
2010).	With	 sustained	 fasting	 (>12–18	h),	 SIRT1	becomes	activated	and	deacetylates	
proteins	like	CRTC2	(Y.	Liu	et	al.	2009)	or	CREBH(Hyunbae	Kim	et	al.	2015c).	This	event	










In	 fact,	we	 show	herein	 that	 expression	 (Figure	3A)	 and	acetylation	 status	of	CREBH	






Other	 possible	 mechanism	 for	 the	 down	 regulation	 of	 Fsp27β	 is	 the	 existence	 of	 a	
repressor	 expressed	 and/or	 activated	 during	 long	 fasting	 period.	 We	 studied	 the	
putative	role	of	REV-ERBα	and	HNF6	since	deletion	of	each	of	those	genes	generates	
animal	 models	 with	 hepatic	 steatosis	 (Y.	 Zhang	 et	 al.	 2016b).	 In	 addition,	 the	
expression	 pattern	 of	 REV-ERBα	 was	 compatible	 with	 this	 role	 (Figure	 R	 3B),	 and	 a	
putative	binding	site	of	Rev-Erbα	has	been	described	in	the	5´	flanking	region	of	mouse	





In	 our	 hands,	 HNF6	 was	 capable	 to	 reduce	 reporter	 assay	 activities,	 but	 promoter-
deletion	 experiments	 shows	 that	 this	 effect	map	 in	 the	 CREBH	 responsive	 element,	
suggesting	a	non-physiologic	squelching	phenomena	(Figure	R	12).	
	
That	 PPARα	 ligands	 are	 products	 of	 the	 de	 novo	 synthesis	 of	 FA	 provides	 a	 link	
between	hepatic	lipogenesis	and	peripheral	FAO.	This	link	can	explain	how	tissues	like	
muscle	oxidize	fatty	acids,	depending	on	circadian	hepatic	synthesis	(S.	Liu	et	al.	2013),	
at	 specific	 times	 coinciding	 to	 the	 animal	 activity.	 However,	 the	 requirement	 of	 de	
novo	synthesis	to	activate	FAO	presents	a	significant	problem	during	the	fasting	state,	
where	PPARα	in	liver	becomes	active	to	promote	FAO	and	ketogenesis	(Kersten	et	al.	
1999),	 but	 there	 is	 not	 any	 endogenous	 ligand	 supply	 available	 by	 diet	 or	 de	 novo	
synthesis.	In	HepG2	cells,	the	forced	expression	of	FSP27α,	blunts	the	PPARα	response	
when	 measured	 by	 using	 a	 PPRE-TK	 reporter	 (Figure	 R	 14).	 The	 response	 of	 the	






The	peculiar	 expression	pattern	of	Fsp27β	 during	 fasting	 (Vilà-Brau	et	 al.	 2013)	may	
explain	 at	 least	 in	 part	 this	 paradox.	 The	 liver	 of	 a	 fasted	 animal	 becomes	 steatotic	
during	 fasting	 because	 of	 the	 fatty	 acids	 (NEFA)	 coming	 from	white	 adipose	 tissue,	
where	lipolysis	is	stimulated.	In	the	liver,	these	fatty	acids	can	serve	as	fuel	to	produce	
ATP	 and	 reducing	 power	 necessary	 for	 gluconeogenesis(McGarry	 and	 Foster	 1995).	
The	 fatty	acids	 liberated	 from	the	adipose	 tissue	are	not	 capable	 to	activate	PPARα,	
but	could	increase,	via	CREBH,	Fsp27β	expression	(Xu	et	al.	2015;	Jaeger	et	al.	2015),	
thus	promoting	the	generation	of	LDs.	The	LDs	created	will	transitorily	accommodate,	







According	 with	 this	 hypothesis,	 when	 we	 turn	 down	 liver	 Fsp27β	 expression,	 the	





will	 induce,	 through	 CREBH-FSP27β	 axis,	 the	 formation	 of	 LDs	 in	 liver,	 which	 are	
needed	 to	 produce	 a	 transitory	 steatosis	 and,	 in	 addition,	 avoid	 the	 release	 of	
endogenous	 PPARα	 ligands	 from	 the	 liver.	 Conversely,	 during	 the	 late	 fasting,	 SIRT1	
activity,	 also	 through	 CREBH	modulation	 (Figure	 R	 7),	 will	 mediate	 FSP27	 clearance	
from	a	liver	that	is	already	prepared	to	oxidize	fatty	acids.	In	turn,	the	increased	FAO	
capacity	 from	 liver	 could	alleviated	ER	 stress	 contributing	 to	CREBH	downregulation.	
During	fed	states,	the	absence	of	Fsp27β	in	liver	will	allow	the	new	synthetized	fat	to	





































































liver	 and	 BAT.	 However,	 its	 function	must	 be	 broader	 because	 its	 expression	 is	 also	
predominant,	with	respect	to	Fsp27α,	in	the	small	intestine.	
The	expression	of	Fsp27β	fluctuates	in	the	liver	during	fasting:	it	increases	during	the	








Fsp27β	 is	a	 target	gene	of	CREBH,	but	not	of	PPARα.	There	 is	no	cross	 talk	between	
both	transcription	factors	in	the	hepatic	expression	of	Fsp27β.	
Fsp27β	 expression	 depends	 on	 the	 level	 of	 acetylation	 of	 CREBH.	 This	 data	 could		
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Scope: Fibroblast growth factor 21 (FGF21) is considered a promising therapeutic candidate
for the treatment of obesity. Since FGF21 production is regulated by various nutritional factors,
we analyze the impact of low protein intake on circulating levels of this growth hormone in
mice and in a sub cohort of the PREDIMED (Prevencio´n con Dieta Mediterra´nea) trial. We also
describe the role of hepatic FGF21 in metabolic adaptation to a low-protein diet (LPD).
Methods and results: We fed control and liver-specific Fgf21 knockout (LFgf21KO) mice a
LPD. This diet increased FGF21 production by inducing its overexpression in liver, and this
correlated with a body weight decrease without changes in food intake. The LPD also caused
FGF21-dependent browning in subcutaneous white adipose tissue (scWAT), as indicated by
an increase in the expression of uncoupling protein 1 (UCP1). In a subgroup of 78 individuals
from the PREDIMED trial, we observed an inverse correlation between protein intake and
circulating FGF21 levels.
Conclusion: Our results reinforce the involvement of FGF21 in coordinating energy home-
ostasis under a range of nutritional conditions. Moreover, here we describe an approach to
increase the endogenous production of FGF21, which if demonstrated functional in humans,
could generate a treatment for obesity.
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1 Introduction
FGF21 (Fibroblast growth factor 21) is considered a promis-
ing therapeutic candidate for the treatment of obesity and
type-2 diabetes. Its administration to obese rodents andmon-
keys leads to decreased plasma concentrations of glucose,
insulin, triglycerides and cholesterol, as well as a reduction
in bodyweight through increased energy expenditure (EE) [1].
The injection of FGF21 in experimental animals induces in-
creased thermogenic capacity by stimulating the expression
of uncoupling protein 1 (UCP1) and type 2 iodothyronine
deiodinase protein 2 (DIO2) in brown adipose tissue (BAT),
and UCP1 in white adipose tissue (WAT), where it produces
the so-called browning process [2,3]. Althoughmost of the ef-
fects of FGF21 have been related to UCP1 expression, it has
also been reported that Ucp1-null mice respond positively
to the pharmacological administration of this growth factor
[4, 5].
FGF21 is a member of the FGF family, which is charac-
terized by endocrine properties. It is produced mainly by the
liver, but also by other tissues such as WAT, BAT, skeletal
muscle, and pancreas [6–9]. Expression of FGF21 in the liver
is induced by fasting, and its transcriptional activity is tightly
controlled by peroxisome proliferator-activated receptor al-
pha (PPAR-) [10–13]. The expression of this growth factor
in liver activates fatty acid oxidation (FAO), ketogenesis, and
gluconeogenesis in this organ, thereby triggering ametabolic
state that mimics long-term fasting [14].
In addition to fasting, FGF21 expression is also induced
in various tissues in response to a number of nutritional chal-
lenges and also to cold exposure. In this regard, FGF21 ex-
pression in BAT is produced in response to cold temperature
[9,15], although it is unclear whether BAT-derived FGF21 acts
as an endocrine factor or whether it is simply an autocrine
factor in the adipose tissue itself.
In mouse liver and HepG2 cells, FGF21 is induced by
leucine-deprivation as part of the transcriptional program
initiated by increased levels of activating transcription fac-
tor 4 (ATF4) [16]. The ATF4-dependent increase in FGF21
expression has been confirmed in mice with autophagy defi-
ciency in skeletal muscle and in liver [17]. Interestingly, these
mice are protected from diet-induced obesity (DIO) and in-
sulin resistance. The similarities in the metabolic responses
between the effects to leucine-deprivation [18] and to FGF21
overexpression allowed us to consider FGF21 as a key media-
tor between amino acid deprivation and lipid metabolism in
liver, WAT, and BAT. In this regard, results from the eval-
uation of the metabolic response of Fgf21-deficient mice to
a leucine-deficient diet previously led us to conclude that, as
expected, most of the effects caused by leucine deprivation
in liver, WAT, and BAT are impaired in the absence of this
growth factor [19].
Likewise, methionine-deprived mice show a phenotype
comparable to that of leucine-deprivation, including resis-
tance to a high-fat diet (HFD), improved glucose homeosta-
sis, increased fatty acid activation and FAO in liver, enhanced
lipolysis in WAT, and increased UCP1 expression in BAT
[20, 21]. Of note, the induction of hepatic FGF21 expression
under leucine- or methionine-restricted diets was found to
be accompanied by an increase in FGF21 protein levels in
serum.
In order to facilitate the translation of these findings to
humans, here we focussed on low-protein diets (LPD) instead
of amino acid-deficient diets. Protein restriction brings about
weight loss and an increase in both food intake and EE [22].
Moreover, a LPD induces thermogenic markers in BAT of
obese rats [23]. Moreover, serum concentrations of FGF21
in both rodents and humans increase upon exposure to an
LPD, regardless of total calorie intake. This observation thus
reveals that FGF21 is likely to be involved in the metabolic
response to protein-restricted diets [24].
Here we addressed whether a LPD exerts similar effects
on lipid metabolism to those of a leucine-deficient diet and
whether these effects are dependent on hepatic FGF21 pro-
duction. To this end, we examined the metabolic response of
wild-type and Fgf21 liver-specific knockout mice (LFgf21KO)
to a LPD (up to 5%of energy as protein). Adecreased indietary
protein content induced a huge increase in FGF21 serum
levels, significant weight loss, and an increase in the expres-
sion of UCP1 in the subcutaneousWAT (scWAT) of wild-type
mice. Remarkably, no effects were observed in Fgf21-deficient
mice, thereby indicating that the absence of FGF21 blunts or
completely blocks the response to a LPD in thismousemodel.
To corroborate these results in humans, we evaluated
whether protein intake is associated with circulating levels
of FGF21. We calculated protein intake through nutritional
questionnaires and determined the serum levels of FGF21
in 78 individuals randomly selected from two nodes of the
PREDIMED (Prevencio´n con Dieta Mediterra´nea) trial. As with
the animal model, an inverse correlation between circulating
FGF21 levels and protein intake was observed.
To summarize, here we define themolecularmechanisms
by which a LPD exerts itsmetabolic effects through the induc-
tion of hepatic FGF21 expression and browning of scWAT.
Furthermore, the data collected from humans raises the pos-
sibility of investigate the dietarymodulation of circulating lev-
els of FGF21 as an alternative approach to its pharmacological
administration. In this regard, we propose the modification
of protein intake to enhance FGF21 production.
2 Material and methods
2.1 Animals
To generate the LFgf21KO mice, Fgf21loxP mice
(Fgf21tm1.2Djm/J) that have Fgf21 flanked by two loxP
sites (Jackson Laboratory, USA) were crossed with Albumin-
cre (Tg(Alb1-cre)1Dlr/J) mice (kindly provided by Dr. A.
Zorzano). The latter express the CRE recombinase enzyme
under control of albumin promoter/enhancer elements,
thus allowing liver-specific gene deletions [25]. Fgf21LoxP
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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mice were used as controls. Animals were housed in a
temperature-controlled room (22 ± 1C) on a 12/12 h
light/dark cycle and were provided free access to commercial
rodent chow and tap water prior to the experiments.
2.1.1 Dietary intervention
The control diet (CD) (Ref. D10001) and LPD (Ref.
D12010401) were obtained from Research Diets, Inc. (USA).
Both diets were isocaloric. They had the following composi-
tion (in percentage ofmass): 20% protein, 66% carbohydrates
and 5% fat for the CD, and 5% protein, 81% carbohydrates
and 5% fat for the LPD (detailed composition shown in Sup-
porting Information Table 1). For the feeding experiment,
8-week-old male mice were first fed the CD for 7 days and
then randomly assigned to either the CD or LPD group with
free access to food and water for 7 days. Food intake and body
weight were recorded daily. Animals were then anesthetized
by isoflurane inhalation, and blood was collected by cardiac
puncture. After euthanizing the animals, tissues were iso-
lated and immediately snap-frozen and stored at −80C for
future analysis. The Animal Ethics Committee of the Univer-
sity of Barcelona approved these experiments (CEEA register:
48/15)
2.1.2 Human samples for plasma measurements
Weused plasma samples from 78men and women randomly
selected from the participants of the centers inHospital Clinic
(Barcelona) and Reus (Tarragona) of the PREDIMED trial
(www.predimed.es). This study was a 5-year randomized clin-
ical trial to compare the effects of either a Mediterranean diet
supplemented with extra virgin olive oil or nuts versus a low-
fat control diet. A total of 7447 asymptomatic men but at high
cardiovascular risk (aged 55–80 years) and women (aged 60–
80 years) were recruited. All participants had type 2 diabetes
or three or more cardiovascular risk factors. Details of the
recruitment method and study design have been described
elsewhere [26] and are also available at www.predimed.es. In
addition to the plasma samples, we also gathered informa-
tion from these 78 individuals, including a 137-item semi-
quantitative food frequency questionnaire (FFQ), and a gen-
eral questionnaire that provided data on lifestyle habits, con-
current diseases, anthropometry, and medication use. Total
energy intake and nutrient intake were calculated on the basis
of Spanish food composition tables [27]. The study protocol
was approved by the institutional review boards of the partic-
ipating centers (ISRCTN35739639).
2.1.3 Plasma measurements
Mouse plasma samples were obtained by centrifuging whole
blood collected in EDTA-treated tube. The plasma was stored
at−80C. FGF21 inmouse and human plasmawasmeasured
by means of a Human (ref. EZHFGF21-19K) and Mouse/Rat
(ref. EZRMFGF21-26K) FGF21 ELISA obtained from EMD
Millipore (Germany). The assay was conducted following the
manufacturer’s protocol. Briefly, a calibration curve was con-
structed by plotting the difference in absorbance values at 450
and 590 nm versus the FGF21 concentrations of the calibra-
tors, and concentrations of unknown samples (performed in
duplicate) were determined using this calibration curve. Free
fatty acids (non-esterified fatty acids, NEFA) were determined
in mice plasma by an enzymatic colorimetric assay. The Free
fatty acids, Half-micro test (ref. 11383175001) was obtained
from Sigma-Aldrich (USA). The measure was performed ac-
cording to the manufacturers’ instructions.
2.1.4 RNA isolation and relative quantitative RT-PCR
Total RNA was extracted from the frozen tissues [liver, epi-
didymal WAT (eWAT), BAT and inguinal scWAT] using TRI
reagent solution (ref. AM9738 Ambion, Thermo Fisher Sci-
entific, USA) followed by DNase I treatment (ref. AM1906,
Ambion, Thermo Fisher Scientific, USA) to eliminate ge-
nomic DNA contamination. To measure the relative mRNA
levels, quantitative (q)RT-PCR was performed using SYBR
Green or TaqMan reagents. cDNA was synthesized from 1
g of total RNA by MLV reverse transcriptase (ref. 28025021,
Invitrogen, ThermoFisher Scientific, USA)with randomhex-
amers (ref. 11034731001, Roche Diagnostics, Germany), fol-
lowing the manufacturer’s instructions. The TaqMan Gene
ExpressionMasterMix (ref. 4369514) and SYBR R© GreenPCR
Master Mix (ref. 4364344), supplied by Applied Biosystems
(ThermoFisher Scientific, USA), were used for the PCR step.
Amplification and detection were performed using the Step-
One Plus Real-Time PCR System (Applied Biosystems, Ther-
moFisher Scientific, USA). EachmRNA from a single sample
was measured in duplicate, using 18S, Beta-Actin, and 36b4
as housekeeping genes. The primer sequences are shown in
Supporting Information Table 2. Results were obtained by
the Relative Standard Curve Method and expressed as fold
increase versus the experimental control.
2.1.5 Protein extracts preparation
To obtain liver nuclear extracts, frozen liver was triturated
with a mortar in liquid nitrogen and immediately homoge-
nized with a Dounce in 1 mL of HB buffer [15 mM Tris-HCl
(pH 8), 15 mM NaCl, 60 mM KCl, 0.5 mM EDTA], and cen-
trifuged at 800 × g for 5 min. The resulting pellet was re-
suspended in 100 L of HB buffer supplemented with 0.05%
TritonX-100 (Sigma,USA) and centrifuged for 10min at 1000
× g. Nuclear pellets were washed with 1mL ofHB buffer sup-
plemented with 0.05% Triton X-100 and 1 mL of HB buffer.
Nuclei were incubated at 4C for 30 min in 50 L of HB
buffer containing 360 mM of KCl and then centrifuged for
5 min at 10 000 × g. The supernatants corresponding to the
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Figure 1. FGF21 is induced by an LPD
in liver but not in BAT or WAT, and
this induction correlates positively with
plasma concentration in mice. Plasma
protein concentration of FGF21 was
measured by ELISA (A). Fgf21 mRNA
levels in liver (B) and WAT and BAT (C)
were measured by qRT-PCR. Error bars
represent the mean ± SEM. **p<0.01
***p<0.001 versus Fgf21LoxP mice fed a
CD (n = 7–9/group).
nuclear extracts were collected, frozen, and stored at −80C.
Protein concentrationwas determined using the Bio-Rad Pro-
tein Assay Dye Reagent Concentrate (Ref. 5000006, Bio Rad,
USA). All buffers were supplemented with a mixture of pro-
tease inhibitors (Ref. P8340, Sigma-Aldrich, USA), 0.1 mM
of PMSF, and a phosphatase inhibitor cocktail 3 (Ref. P0044,
Sigma-Aldrich, USA).
2.1.6 Immunoblotting
Nuclear proteins were resolved by SDS-polyacrylamide gel
electrophoresis and transferred onto a Hybond-P PVDF
membrane (Millipore). Membranes were blocked (Tris-HCl
50 mM pH 8, 150 mM, 5% skimmed milk, 0.1% Tween) for
1 h at room temperature. The blots were then incubated with
ATF4 primary antibody (sc-200, Santa Cruz Biotechnology,
Inc., USA) in blocking solution (1:200). After an overnight
incubation at 4C, the blots were washed and incubated with
an anti-rabbit horseradish peroxidase-conjugated secondary
antibody (ref. NA934, Amersham, GE Healthcare, UK) in
blocking buffer for 2 h at room temperature. The blots were
developed using the EZ-ECL Chemiluminescence Detection
Kit for HRP (ref. 20-500-500, Biological Industries, Israel).
Quantification was performed using Image J software.
2.1.7 Data analysis/statistics
For human samples, baseline characteristics are presented
as means ± standard error of the mean (SEM) for contin-
uous variables, frequencies and percentages for categorical
variables across quartiles of protein intake at baseline. Dif-
ferences between quartiles were tested by a 1-factor ANOVA
test for continuous variables and by the chi-square test for
the categorical ones. We performed multiple linear regres-
sions to evaluate the relationship between protein intake
(exposure variable) and FGF21 hormone levels (dependent
variable). Protein intake was previously adjusted for calories
using the residual method. Regression analyses were unad-
justed (model 1) or adjusted by body mass index (BMI) and
total energy intake (model 2).
All statistical analyseswere conductedusingSAS software,
version 9.3 (SAS Institute, Inc., USA). All t tests were two-
sided and p values below 0.05 were considered statistically
significant.
3 Results and discussion
3.1 A LPD induces FGF21 gene expression in the
liver of control mice, but not in BAT or WAT
According to previously reported results, mice on an LPD
show a dramatic increase in serum levels of FGF21 [22–24]
(Fig. 1A). To check the origin of this FGF21, we analyzed
the Fgf21 mRNA levels in several tissues. The liver is the
main site of FGF21 production and release into the blood.
Accordingly, we observed a great induction of Fgf21 mRNA
synthesis in the liver of mice on the LPD (Fig. 1B). This
increase correlated positively with serum levels. In contrast,
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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Fgf21 expression was unchanged in BAT, eWAT and scWAT
of control mice (Fgf21loxP) on the same diet (Fig. 1C).
To determine the specific role of hepatic FGF21 in the
metabolic response to a LPD, we fed LFgf21KO mice a LPD
diet. As expected, Fgf21 mRNA levels were undetectable in
the livers of these animals (Fig. 1B), while no statistically
significant changes were detected in BAT, eWAT, or scWAT
when compared to the same tissues in control mice (Fig. 1C).
This mouse model shows that protein restriction almost
exclusively affects the hepatic expression of FGF21 and that
there is no compensatory response in other tissues, such as
BAT or WAT.
We measured the circulating FFA levels as a possible sig-
naling factor for the induction of FGF21 in mice under a low
protein diet. The absence of statistically significant changes
in FFA (data not shown) allow us to rule out the PPAR-FA axis
in the signaling mechanism responsible for the induction of
the hepatic expression of FGF21 in these conditions.
3.2 A LPD increases ATF4 protein levels in mouse
liver
GCN2 is a kinase that acts as a sensor of amino acid sup-
ply [28]. When activated, GCN2 phosphorylates EIF2a, which
results in the slowing or stalling of the initiation step of
mRNA translation. Hence, phospho-EIF2a reduces general
protein synthesis rates. Paradoxically, in these circumstances
there is an increase in the translation of discrete mRNAs,
including ATF4 [29, 30]. A LPD increases GCN2-dependent
phosphorylation of eIF2a, resulting in greater levels of ATF4
protein [31, 32]. ATF4 is a transcriptional factor that directly
or indirectly induces a subset of specific genes to regulate
metabolic adaptation to amino acid restriction. The 5’ region
of Fgf21 contains two evolutionarily conserved functional
ATF4-binding sequences responsible for its ATF4-dependent
transcriptional activation [16, 33]. To determine the effect of
anLPDonATF4 expression,we analyzed liver protein extracts
of mice fed an LPD or a CD for 7 days. ATF4 expression was
induced in liver in response to the LPD, as revealed by West-
ern blot assays (Fig. 2A and B). These results are consistent
with previous published data reporting that ATF4 triggers
the expression of FGF21 and that Gcn2 -/- mice show a par-
tially blunted induction of FGF21 under protein restriction
[24]. On the basis of the aforementioned published data, our
results support the notion that the GCN2-ATF4 pathway is
likely to be the main mechanism underlying hepatic FGF21
overexpression upon protein restriction.
GCN2-independent mechanisms that induce hepatic
FGF21 in response to methionine-restricted diets have re-
cently been described [34]. This observation points to a
different response program in liver via a non-canonical
PERK/nuclear respiratory factor 2 (NRF2) pathway. This al-
ternative pathway could effectively sense and translate the
metabolic responses to methionine restriction in the absence
of GCN2. In parallel, the absence of GCN2 during long-term
Figure 2. An LPD increases ATF4 protein levels in liver. ATF4
protein levels were determined by Western blot analysis using
hepatic nuclear extracts obtained from Fgf21LoxP mice adminis-
tered a CD or LPD (A). The experiment was normalized by actin
protein levels as loading control and the intensity of the bands
were quantified by densitometry with the Image J software (B).
Error bars represent the mean ± SEM. **p<0.01 versus CD (n =
3/group).
dietary protein restriction has been reported to be compen-
sated upstream of ATF4 to induce FGF21 [35]. Globally, the
impact of alternative pathways to stimulate FGF21 expression
under a LPD, whether they involve ATF4 or not, should be
addressed in greater depth.
3.3 Fgf21 deficiency significantly attenuates weight
loss under an LPD
Mice fed an LPD presented rapid weight loss. Here we ad-
dressed whether this phenomenon is dependent on hepatic
FGF21. For this purpose, Fgf21LoxP mice and LFgf21KO mice
were fed a CD or LPD for 7 days.
Our data showed that weight loss was partially blunted
in LFgf21KO mice (Fig. 3A and B). However, the reduction
in food intake observed under an LPD, that can account for
some of the loss in body weight, was unchanged between
genotypes (Fig. 3C). It is remarkable that these results con-
tradicted previous publications describing either no change
or an increase in food intake in response to protein restriction
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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Figure 3. Hepatic FGF21 expression is required for the weight loss caused by LPD but does not affect food consumption. Body weight
progression of mice fed a CD or LPD expressed as percentage of the initial weight, which was considered 100% (A). Total body weight
change (g) after 7 days on a CD or LPD (B). Daily food intake (C). Error bars represent the mean ± SEM. **p<0.01 versus Fgf21LoxP mice fed
a CD, #p<0.05 versus LFgf21KO fed a CD; 0.07 represents p value versus LFgf21KO mice fed a CD (n = 7–9/group).
[24]. Nonetheless, the present results are consistent with the
decreased food intake described in mice fed leucine-deficient
diets [19]. Minor changes in diet composition affecting amino
acid bioavailability may explain these discrepancies. More-
over, although FGF21 has the potential to modulate food
preferences [36, 37]. In our mouse model this FGF21 did not
contribute to the food aversion caused by the LPD.
To determine the importance of each tissue in overall
weight loss, we calculated the change in weight of individ-
ual tissues. All tissues analyzed tended to weigh less in mice
on the LPD, reaching statistical significance in heart, liver,
scWAT and p = 0.06 in eWAT (Fig. 4). Regarding the role
of FGF21, our results show that the weight loss observed in
scWAT and heart was dependent on hepatic FGF21 expres-
sion, as weight loss was blunted in LFgf21KOmice under the
same diet. The effect of the LPD on liver tissue weight was
partially abolished by hepatic Fgf21 deficiency (Fig. 4).
Taken together, FGF21 produced by the liver is, at least in
part, responsible for the body weight loss experienced by the
mice on the LPD.Our results point to scWAT as one of the tar-
get tissues of hepatic FGF21 regarding the weight loss effect.
Since hepatic FGF21 exerts its effects mainly in WAT and
BAT through regulating lipid metabolism, the following ex-
periments are focused on describing the role of LPD-induced
FGF21 on the metabolic response of adipose depots.
3.4 LPD induces metabolic changes in response to
FGF21 in scWAT, but not in eWAT or BAT
Thermogenesis in BAT is mediated by the upregulation of
UCP1 [38]. It has been proposed that the induction of FGF21
production by the liver mediates direct activation of brown
fat thermogenesis during the fetal-to-neonatal transition [39].
FGF21 also regulates peroxisome proliferator-activated re-
ceptor gamma coactivator 1-alpha (PGC1a) and browning of
WAT in adaptive thermogenesis [40].
Contrary to what happens under leucine deprivation [19],
no statistically significant induction of Ucp1 or Dio2 mRNA
levels were observed in BAT or eWAT of control mice under
the LPD (Fig. 5A and B). In contrast, the analysis of gene
expression in scWAT revealed that the LPD induced the ex-
pression ofUcp1, Pgc1a, Cidea and PR domain containing 16
(Prdm16), reaching a statistically significant value for Ucp1
and Pgc1a (Fig. 6). This expression pattern was not detected
in the LFgf21KO mice (Fig. 6), thereby indicating the role
Figure 4. Hepatic FGF21 is required for the
weight loss caused by an LPD. The weight
of heart, liver, eWAT, scWAT, BAT, and gas-
trocnemius in mice fed a CD or LPD is
presented as the mg of tissue per 100 mg
of total body weight. Error bars represent
the mean ± SEM. *p<0.05, ***p<0.001
versus Fgf21LoxP mice fed a CD; #p<0.05,
##p<0.01 versus LFgf21KO mice fed a CD;
0.06 represents the p value with respect to
Fgf21LoxP mice fed a CD (n = 7–9/group).
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Figure 5. A LPD does not alter thermogenic genes in BAT or
eWAT. Ucp1 and Dio2 expression was measured by qRT-PCR in
mouse BAT and eWAT. Error bars represent the mean ± SEM.
*p<0.05 versus Fgf21LoxP mice fed a CD (n = 7–9/group).
of FGF21 in the metabolic adaptation of scWAT to protein
restriction.
As UCP1 activity is related to EE, the blunted induction
of UCP1 in the LFgf21KO mice under LPD may contribute
to the lower weight loss observed in this mouse model under
these circumstances. In conclusion, hepatic FGF21 induces
the browning of scWAT and increases the thermogenic ca-
pacity of mice on an LPD.
3.5 FGF21 plasma levels correlate negatively with
protein intake in humans
To translate our results to humans, we evaluated the relation-
ship between protein intake and circulating levels of FGF21
in 78 individuals randomly selected from the PREDIMED
trial. Baseline data for these subjects are shown in Table 1.
Protein intake was obtained from FFQs and was expressed
as grams of protein per day (g/day). We used baseline sam-
ples (T = 0). Results from the multiple linear regression
analyses showed a significant inverse relationship between
plasma FGF21 concentrations and dietary intake of protein.
At baseline, FGF21 levels decreased by 3.39 pg/mL for each
gram of protein ingested (Table 2). The participants with a
high intake of protein showed statistically significant lower
values of circulating FGF21.
We also performed regression analyses using quartiles of
protein intake and obtained similar results. After adjustment
for BMI and total energy intake, FGF21 decreased (−30.7
pg/mL) when moving from the lower to higher quartiles (p
= 0.015)(Fig. 7).
Similarly to the data frommice, these results indicate that
the serumconcentrations of FGF21 are inversely proportional
to dietary protein intake.
4 Concluding remarks
Here we addressed the role of hepatic FGF21 in themetabolic
changes triggered by an LPD. Our results demonstrate that
the effects of anLPDdepend, at least in part, on the circulating
levels of FGF21 and consequently on the liver production of
Figure 6. Hepatic FGF21 is required
for inducing thermogenic gene expres-
sion during an LPD. Ucp1, Dio2, Pgc1a,
Pparg, Prmd16, and Cidea expression
was measured by qRT-PCR in mouse
scWAT. Error bars represent the mean
± SEM. *p<0.05 versus Fgf21LoxP mice
fed a CD (n = 7–9/group).
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Table 1. Baseline characteristics of participants from the PREDIMED cohort included in this study, divided into quartiles of energy-adjusted
protein intake at baselinea)
Quartiles of energy-adjusted protein intake p valueb)
Q1 Q2 Q3 Q4
No subjects (78) 19 20 20 19
Age (years) 67.1 ± 5.9 65.7 ± 4.8 67.0 ± 6.4 65.3 ± 4.0 0.30
Sex (women) 6 (31) 10 (50) 9 (45) 15 (79) 0.03
Body mass index (kg/m2) 28.1 ± 3.2 30.0 ± 3.4 27.7 ± 2.7 30.8 ± 2.9 0.006
Energy intake (kcal/day) 2370 ± 350 2192 ± 603 2227 ± 433 2390 ± 571 0.51
Protein intake (g/day) 80 ± 6 90 ± 2 97 ± 3 110 ± 5 <0.0001
FGF21 (pg/mL) 289 ± 116 276 ± 143 256 ± 117 190 ± 115 0.07
a)Categorical variables: subjects (percentage), continuous variables: mean ± SD
b)One-way ANOVA tests (continuous variables) or chi-squared tests (categorical variables).
Table 2. Multivariable regression analyseswith FGF21 (pg/mL) as
dependent variable and energy-adjusted protein intake
at baseline (g/day) as independent variable




Model 1b) −3.42 0.006 −5.83, −1.02




Model 1b) −31.5 0.01 −56.5, −6.5




c)Adjusted for body mass index (BMI) and total energy intake.
Figure 7. Circulating FGF21 levels correlate negatively with pro-
tein intake. Plasma FGF21 concentration divided into quartiles of
protein intake adjusted for the calorie intake of 78 participants
in the PREDIMED trial. Error bars represent the mean ± SEM.
*p<0,05 from first quartile; #p<0,05 from the second quartile.
this growth factor. The LFgf21KO mice revealed the
relevance of FGF21 in the response to an LPD, but also
in the metabolic and transcriptional pathways activated or
repressed by protein restriction.
Given the parallelism between the results of our study in
humans and those in mice, we postulate that dietary protein
content is crucial for the modulation of circulating FGF21
levels and thus for the activity of this hormone in target tissues
in mice and that it could also be in humans. We propose to
investigate a dietary intervention consisting of a reduction
in protein intake as a non-invasive approach to induce the
hepatic expression of FGF21. We also describe the molecular
mechanisms through which a LPD—via FGF21—could be
beneficial to restore lipid/glucose homeostasis.
Studies performed in humans provide contradictory re-
sults regarding the correlation between plasma levels of
FGF21, BMI, and insulin resistance [41–43]. Also, the FGF21-
resistant state described inmice [44] is not well established in
humans and the beneficial effects of FGF21 induction have
yet to be demonstrated in the latter.
Our findings provide new insight into the modulation of
dietary protein as a strategy to induce elevated serum concen-
trations of FGF21. Further studies will be needed to evaluate
the effects of an LPD / FGF21 induction on the metabolic
profile of obese and insulin-resistant subjects.
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Fibroblast growth factor 21 (FGF21) is considered a promising therapeutic candidate for the 
treatment of obesity and metabolic disorders. Since FGF21 production is regulated by 
various nutritional factors, we analyze the impact of low protein intake on circulating levels of 
this growth hormone in mice and in a sub cohort of the PREDIMED (Prevención con Dieta 
Mediterránea) trial. We also describe the role of hepatic FGF21 in metabolic adaptation to a 




We fed control and liver-specific Fgf21 knockout (LFgf21KO) mice a LPD. This diet 
increased FGF21 production by inducing its overexpression in liver (Figure 1), and this 
correlated with the induction of the transcription factor ATF4 (Figure 2) and a body weight 
decrease without changes in food intake (Figure 3).  
Figure 1. FGF21 is induced by a LPD in liver, and this induction correlates positively 
with plasma concentration in mice. Plasma protein concentration of FGF21 was 
measured by ELISA (A). Fgf21 mRNA levels in liver (B) were measured by qRT-PCR. Error 
bars represent the mean ± SEM. ** p<0.01 ***p<0.001 versus Fgf21LoxP mice fed a CD 
(n=7–9/group).  
Figure 2. A LPD increases ATF4 protein 
levels in liver. ATF4 protein levels were 
determined by Western blot analysis using 
hepatic nuclear extracts obtained from 
Fgf21LoxP mice administered a CD or LPD (A). 
The experiment was normalized by actin protein 
levels as loading control and the intensity of the 
bands were quantified by densitometry with the 
Image J software (B). Error bars represent the 
mean ± SEM. **p<0.01 versus CD. (n=3/group). 
Figure 3. Hepatic FGF21 expression is required for the weight loss caused by LPD but 
does not affect food consumption. Body weight progression of mice fed a CD or LPD 
expressed as percentage of the initial weight, which was considered 100% (A). Total body 
weight change (g) after 7 days on a CD or LPD (B). Daily food intake (C). Error bars 
represent the mean ± SEM. ** p<0.01 versus Fgf21LoxP mice fed a CD, # p<0.05 versus 
LFgf21KO fed a CD; 0.07 represents p value versus LFgf21KO mice fed a CD (n=7–9/
group).  
The LPD also caused FGF21-dependent browning in subcutaneous white adipose tissue 
(scWAT), as indicated by an increase in the expression of uncoupling protein 1 (UCP1) 
(Figure 4).  
Figure 4. Hepatic FGF21 is required for inducing thermogenic gene expression during 
a LPD. Ucp1, Dio2, Pgc1a, Pparg, Prmd16 and Cidea expression was measured by qRT-
PCR in mouse scWAT. Error bars represent the mean ± SEM. * p<0.05 versus Fgf21LoxP 
mice fed a CD (n=7–9/group). 
In a subgroup of 78 individuals from the PREDIMED trial, we observed an inverse 
correlation between protein intake and circulating FGF21 levels (Figure 5).  
Figure 5. Circulating FGF21 levels correlate negatively with protein intake. Plasma 
FGF21 concentration divided into quartiles of protein intake adjusted for the calorie intake of 
78 participants in the PREDIMED trial. Error bars represent the mean ± SEM. * p<0,05 from 
1st quartile; # p<0,05 from the 2nd quartile.  
GRAPHIC ABSTRACT 
 
Our results reinforce the involvement of FGF21 in coordinating energy homeostasis under a 
range of nutritional conditions. Moreover, here we describe an approach to increase the 
endogenous production of FGF21, which if demonstrated functional in humans, could 
generate a treatment for obesity. 
 
